Nektar Therapeutics Share Price
NASDAQ: NKTR | Small CapNektar Therapeutics Stock Performance
Open $73.16 | Prev. Close $74.51 | Circuit Range N/A |
Day Range $71.23 - $73.51 | Year Range $28.03 - $108.83 | Volume 23,468 |
Average Traded $72.19 |
Nektar Therapeutics Share Price Today
As of 31 August 2026, Nektar Therapeutics's share price is $72.56. The stock opened at $73.16, compared to its previous close of $74.51. During today's trading session, Nektar Therapeutics's share price traded between $71.23 and $73.51, with an average price of $72.37. Over the past 52 weeks, the stock has recorded a high of $108.83 and a low of $28.03. In terms of performance, Nektar Therapeutics's share price has risen by 5.27% over the last six months and is up 143.30% on a year-on-year basis.
Nektar Therapeutics Share Price Chart
Nektar Therapeutics Stock Fundamentals & Key Indicators
Market Cap $1.22B | PE Ratio (TTM) -7.46 | Dividend Yield N/A |
EPS (TTM) $-9.73 | Revenue (TTM) $55.23M | Return On Equity (TTM) -182.65% |
Profit Margin -297.07% | Debt to Equity 0.60 | Quarterly Earnings Growth YoY 4.14% |
Nektar Therapeutics Quarterly Profit & Loss
All figures in USD
Nektar Therapeutics Annual Profit & Loss
All figures in USD
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $69.28 | $74.53 | +5.43% |
Jul 2026 | $68.80 | $70.69 | +1.33% |
Jun 2026 | $64.50 | $69.76 | +7.62% |
May 2026 | $85.00 | $64.82 | -23.81% |
Apr 2026 | $72.59 | $85.08 | +18.31% |
Mar 2026 | $68.56 | $71.92 | +4.33% |
Feb 2026 | $38.18 | $68.93 | +84.55% |
Jan 2026 | $42.62 | $37.35 | -11.61% |
Dec 2025 | $64.31 | $42.26 | -35.08% |
Nov 2025 | $62.41 | $65.09 | +0.29% |
Oct 2025 | $57.98 | $64.90 | +14.10% |
Sep 2025 | $29.52 | $56.88 | +90.71% |
NKTR Share Price FAQs
What is Nektar Therapeutics share price today?
What is the 52 week high and 52 week low of Nektar Therapeutics stock?
What is NKTR's market capitalisation today?
What is NKTR's net income for the last quarter?
What is the 5 year returns of NKTR?
What is the high & low stock price of NKTR today?
Can I buy NKTR shares in India?